Skip to main content

Table 3 Phenotypes, treatment and outcomes of the patients with missense and non-frameshift pathogenic variants

From: Genotype-phenotype correlations of STXBP1 pathogenic variants and the treatment choices for STXBP1-related disorders in China

Patient number

Pathogenic variant type

Sex

Current age (y)

Diagnosis

Seizure onset age

Initial seizure semiology (s)

Latest seizure semiology (s)

EEG manifestations

MRI findings

Previous medicine (s)

Recent medicine (s)

Efficient medicine (s)

Seizure outcome (age)

Muscle tone

Degree of ID/GDD

P1

Missense

F

5.4

OS evolved to WS

2m10d

FS

TS, S, FMS, FCS

H/BS/M

A

TPM,VPA, ACTH and PRD

LEV

ACTH and LEV

NSF

High

Profound

P3

Missense

F

5.3

EOEE evolved to WS

16d

FS

FS, S

M

N

PB and LEV

LEV

PB and LEV

SF (0.3 y)

Normal

Severe

P4

Missense

M

11.3

WS

2 m

TCS, S

TCS, S

ESE/H/ M

A

VPA, TPM, ACTH and PRD

No medication

VPA and ACTH

SF (1 y)

High

Profound

P5

Missense

M

Died

OS evolved to WS

2d

FS, S

TS, S, FS,

H/BS

A

LEV

Died

-

Died (2 y)

High

Died

P6

Missense

F

9.8

ID, EP

7 m

TS

TS

No results

No results

No medicine

No medicine

No medicine

NSF

Low/high

Profound

P7

Missense

M

4.8

OS evolved to WS

1m19d

S

S, FS, FS-GTS

H/BS/W/F

N

LEV, TPM, ACTH, CZP, and NZP

LEV

ACTH

SF (0.6 y)

Normal

Severe

P8

Missense

M

Died

OS evolved to WS

2m28d

TS, S

S, TS

BS/F

A

VPA and ACTH

Died

None

Died (0.5 y)

Normal

Died

P9

Missense

F

9

OS evolved to WS

0.5 m

S, TS

S, FS, T

H/BS/M/W

N

TPM, ACTH, PRD, LEV, NZP, and VNS

LEV, TPM

None

NSF

High

Profound

P12

Missense

M

7.8

ID

10 m

Not applicable

Not applicable

Slow back ground

N

Not applicable

Not applicable

Not applicable

Not applicable

High

Profound

P13

Missense

F

13

ID, EP

5 m

TS

TS

W

A

LEV

No medication

LEV

SF (10y)

Normal

Moderate

P14

Missense

F

4.1

GDD, EP

1y3m

TS

TS, FS

M

N

VPA and LEV

LEV

LEV

NSF

Normal

Mild

P15

Missense

F

5.6

WS

2d

FS

FS, S

M

N

TPM and VPA

TPM, VPA

TPM and VPA

SF (2y)

Low

Severe

P16

Non frameshift

F

5.8

WS

7d

S

S, TS

H/W

N

VPA, ACTH, and VGB

VPA

ACTH and VGB

NSF

Low

Severe

P17

Missense

F

5.4

EOEE evolved to WS

1m23d

FS

FS, TS, S

W

N

LEV, TPM, and VPA

LEV and VPA

LEV and VPA

SF (2y)

Normal

Profound

P18

Non frameshift

F

5.4

EOEE evolved to WS

4 m

TS

TS, S, FS,

W/H/F

N

LEV, VPA, ACTH, KD, VGB, and CLB

VGB

LEV, VPA and VGB

NSF

Low

Profound

  1. Abbreviations: A; abnormal, BS; burst-suppression, d; day, EOEE; early onset epileptic encephalopathy, EEG; electroencephalography, ESE; epileptic status epilepticus, F; female, FCS; focal-clonic seizures, FS; focal seizures, FS-GTCS; focal seizures secondary to generalized tonic-clonic seizures, FS-S; focal spasm seizures, AAS; atypical aphasia, GDD; global developmental delay, H; hypsarrhythmia, ID; intellectual disability, m; month, M; male; MRI; magnetic resonance imaging, M; multifocal discharge, N; normal, OS- ohtahara syndrome, S; spasms seizures, TS; tonic seizures, TCS; tonic clonic seizures, W; widespread discharge, WS; west syndrome, ACTH; adrenocorticotropic hormone, CZP; clonazepam, KD; ketogenic diet, LEV; levetiracetam, NZP; nitrazepam, PRD; prednisone tablets, PB; phenobarbital, P; patient, TPM; topiramate, VPA; sodium valproate, VGB; vigabatrin, CLB; clobazam, VNS; vagus nerve stimulation, SF; seizure free, NS; not seizure-free